FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2242585528> ?p ?o ?g. }

• W2242585528 endingPage "5523" @default.
• W2242585528 startingPage "5523" @default.
• W2242585528 abstract "5523 Background: More efficacious, less toxic combinations are needed to treat platinum-sensitive recurrent ovarian cancer. Pemetrexed (Pem) is a multitargeted antifolate that has a manageable toxicity profile and has been combined with carboplatin in other cancers. Methods: Phase II study of carboplatin AUC 5 with Pem 500 mg/m2 both administered IV on day 1, with Decadron, B12, and folate premedication, and given every 21 d for six cycles with the possibility of receiving 8 if benefit derived. Eligibility included platinum sensitive (>6 mos without progression after last platinum regimen), measurable (by RECIST) recurrent ovarian, peritoneal, or fallopian tube cancer, PS ≤ 2, ≤ 2 prior regimens for recurrence, and normal bone marrow, liver/renal function. Primary objective was response rate. Other endpoints included toxicities, time to progression (TTP), and survival. A RR of ≥ 31% was considered worthy of further phase III testing. Results: 45 patients have been enrolled, and accrual is complete. 1 pt was ineligible. 3 pts withdrew before 2 cycles were completed because of grade 3 fatigue/weakness, grade 3 diarrhea and a carboplatin reaction, respectively and were not evaluated for response. 27 pts completed at least 6 cycles. No dose reductions (DR’s) were required because of toxicities in 28 of 41 pts who received at least 2 cycles. 13 pts had DR’s as a result of myelosuppression or GI toxicity; 11 had one DR and 2 had two DR’s. 44 pts are evaluable for toxicities. Grade 3 and 4 toxicities are as follows: neutropenia (19 pts), platelets (11 pts), leukopenia (7 pts), anemia (4 pts), fatigue (4 pts), nausea (2 pts), diarrhea (2 pts), dizziness (2 pts), and 1 pt each experienced hypokalemia, vomiting, constipation, anorexia, memory impairment, pulmonary embolism. 14 pts had a carboplatin allergy. No significant rashes nor mucositis occurred. 41 pts were evaluable for RR, TTP, and survival. Overall RR was 61%; 1CR (2%), 24 PR’s (59%), 14 SD (34%), and 2 PD (5%). Median TTP was 4.6 months (95% CI 3.2 -5.9) while median PFS was 7.7 months (95% CI 6.7 - 10.1). Conclusions: Carboplatin/Pem is a well-tolerated regimen with significant activity in platinum-sensitive recurrent ovarian cancer. Further testing of this regimen in this population is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Lilly Oncology" @default.
• W2242585528 created "2016-06-24" @default.
• W2242585528 creator A5026616005 @default.
• W2242585528 creator A5028666189 @default.
• W2242585528 creator A5030257115 @default.
• W2242585528 creator A5033018791 @default.
• W2242585528 creator A5034449508 @default.
• W2242585528 creator A5052565759 @default.
• W2242585528 creator A5054372225 @default.
• W2242585528 creator A5058249824 @default.
• W2242585528 creator A5088910638 @default.
• W2242585528 creator A5091757228 @default.
• W2242585528 date "2008-05-20" @default.
• W2242585528 modified "2023-09-24" @default.
• W2242585528 title "Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer" @default.
• W2242585528 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.5523" @default.
• W2242585528 hasPublicationYear "2008" @default.
• W2242585528 type Work @default.
• W2242585528 sameAs 2242585528 @default.
• W2242585528 citedByCount "1" @default.
• W2242585528 crossrefType "journal-article" @default.
• W2242585528 hasAuthorship W2242585528A5026616005 @default.
• W2242585528 hasAuthorship W2242585528A5028666189 @default.
• W2242585528 hasAuthorship W2242585528A5030257115 @default.
• W2242585528 hasAuthorship W2242585528A5033018791 @default.
• W2242585528 hasAuthorship W2242585528A5034449508 @default.
• W2242585528 hasAuthorship W2242585528A5052565759 @default.
• W2242585528 hasAuthorship W2242585528A5054372225 @default.
• W2242585528 hasAuthorship W2242585528A5058249824 @default.
• W2242585528 hasAuthorship W2242585528A5088910638 @default.
• W2242585528 hasAuthorship W2242585528A5091757228 @default.
• W2242585528 hasConcept C121608353 @default.
• W2242585528 hasConcept C126322002 @default.
• W2242585528 hasConcept C141071460 @default.
• W2242585528 hasConcept C143998085 @default.
• W2242585528 hasConcept C2776694085 @default.
• W2242585528 hasConcept C2777063308 @default.
• W2242585528 hasConcept C2777240266 @default.
• W2242585528 hasConcept C2778239845 @default.
• W2242585528 hasConcept C2780427987 @default.
• W2242585528 hasConcept C2780873365 @default.
• W2242585528 hasConcept C2781413609 @default.
• W2242585528 hasConcept C2781451048 @default.
• W2242585528 hasConcept C29730261 @default.
• W2242585528 hasConcept C31760486 @default.
• W2242585528 hasConcept C71924100 @default.
• W2242585528 hasConcept C90924648 @default.
• W2242585528 hasConceptScore W2242585528C121608353 @default.
• W2242585528 hasConceptScore W2242585528C126322002 @default.
• W2242585528 hasConceptScore W2242585528C141071460 @default.
• W2242585528 hasConceptScore W2242585528C143998085 @default.
• W2242585528 hasConceptScore W2242585528C2776694085 @default.
• W2242585528 hasConceptScore W2242585528C2777063308 @default.
• W2242585528 hasConceptScore W2242585528C2777240266 @default.
• W2242585528 hasConceptScore W2242585528C2778239845 @default.
• W2242585528 hasConceptScore W2242585528C2780427987 @default.
• W2242585528 hasConceptScore W2242585528C2780873365 @default.
• W2242585528 hasConceptScore W2242585528C2781413609 @default.
• W2242585528 hasConceptScore W2242585528C2781451048 @default.
• W2242585528 hasConceptScore W2242585528C29730261 @default.
• W2242585528 hasConceptScore W2242585528C31760486 @default.
• W2242585528 hasConceptScore W2242585528C71924100 @default.
• W2242585528 hasConceptScore W2242585528C90924648 @default.
• W2242585528 hasIssue "15_suppl" @default.
• W2242585528 hasLocation W22425855281 @default.
• W2242585528 hasOpenAccess W2242585528 @default.
• W2242585528 hasPrimaryLocation W22425855281 @default.
• W2242585528 hasRelatedWork W1975832547 @default.
• W2242585528 hasRelatedWork W2025149885 @default.
• W2242585528 hasRelatedWork W2055225731 @default.
• W2242585528 hasRelatedWork W2111140446 @default.
• W2242585528 hasRelatedWork W2162225583 @default.
• W2242585528 hasRelatedWork W2242585528 @default.
• W2242585528 hasRelatedWork W2332662352 @default.
• W2242585528 hasRelatedWork W2336050317 @default.
• W2242585528 hasRelatedWork W2978897255 @default.
• W2242585528 hasRelatedWork W3107991554 @default.
• W2242585528 hasVolume "26" @default.
• W2242585528 isParatext "false" @default.
• W2242585528 isRetracted "false" @default.
• W2242585528 magId "2242585528" @default.
• W2242585528 workType "article" @default.